Format

Send to

Choose Destination
Crit Care Clin. 2018 Jan;34(1):97-106. doi: 10.1016/j.ccc.2017.08.007. Epub 2017 Oct 6.

Management of Sepsis-Induced Immunosuppression.

Author information

1
Laboratoire d'Immunologie, Cellular Immunology Laboratory, Hospices Civils de Lyon, Hôpital Edouard Herriot, Pavillon E - 5 place d'Arsonval, Lyon Cedex 03 69437, France; EA 7426 PI3 "Pathophysiology of Injury-induced Immunosuppression", Université Claude Bernard Lyon I, Hospices Civils de Lyon, bioMérieux, Hôpital Edouard Herriot, Place d'Arsonval, Lyon Cedex 03 69437, France.
2
EA 7426 PI3 "Pathophysiology of Injury-induced Immunosuppression", Université Claude Bernard Lyon I, Hospices Civils de Lyon, bioMérieux, Hôpital Edouard Herriot, Place d'Arsonval, Lyon Cedex 03 69437, France; Departement of Anesthesiology, Hospices Civils de Lyon, Hôpital Edouard Herriot, Pavillon E - 5 place d'Arsonval, Lyon Cedex 03 69437, France.
3
Laboratoire d'Immunologie, Cellular Immunology Laboratory, Hospices Civils de Lyon, Hôpital Edouard Herriot, Pavillon E - 5 place d'Arsonval, Lyon Cedex 03 69437, France; EA 7426 PI3 "Pathophysiology of Injury-induced Immunosuppression", Université Claude Bernard Lyon I, Hospices Civils de Lyon, bioMérieux, Hôpital Edouard Herriot, Place d'Arsonval, Lyon Cedex 03 69437, France; TRIGGERSEP (TRIal Group for Global Evaluation and Research in SEPsis), F-CRIN Network, France. Electronic address: guillaume.monneret@chu-lyon.fr.

Abstract

It is now well established that profound immunosuppression develops within a few days after sepsis onset in patients. This should be considered additional organ failure because it is associated with increased rate of nosocomial infections, mortality, and long-term complications, thus constituting the rationale for immunomodulation in patients. Nevertheless, the demonstration of the efficacy of such therapeutic strategy in improving deleterious outcomes in sepsis remains to be made. Results from clinical trials based on interleukin 7 and granulocyte macrophage colony-stimulating factor immunoadjuvant therapies in septic shock patients are expected for 2018.

KEYWORDS:

GM-CSF; HLA-DR; IL-7; Immunostimulation; Immunosuppression; Lymphopenia; Sepsis; Septic shock

PMID:
29149944
DOI:
10.1016/j.ccc.2017.08.007
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center